Citations

Showing 10 of 108162 citations.

In situ Generation of Antibiotics using Bioorthogonal “Nanofactories”
Li, Cheng‐Hsuan , Huang, Rui , Schmidt-Malan, Suzannah M., Schmidt-Malan, Suzannah, Makabenta, Jessa Marie , Patel, Robin , Rotello, Vincent M.

Mayo Clinic

Microbiology Insights | February 24, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1178636121997121 | PMID 33707951 Get It

Prodrug strategies use chemical modifications to improve the pharmacokinetic properties and therefore therapeutic effects of parent drugs. Traditional prodrug approaches use endogenous enzymes for activation. Bioorthogonal catalysis uses processes that endogenous enzymes cannot access, providing a complementary strategy for prodrug uncaging. Site-selective activation of prodrugs to drugs (uncaging) using synthetic catalysts is a promising strategy for localized drug activation. We discuss here recent studies that incorporate metal catalysts into polymers and nanoparticle scaffolds to provide biocompatible “enzyme-like” catalysts that can penetrate bacterial biofilms and activate prodrug antibiotics in situ, affording a new strategy to treat bacterial biofilm infections with the potential for reduced off-target effects.
Self-contained system for mitigation of contaminated aerosol sources of SARS-CoV-2 
Patel, B. M. , Forzani, Erica , Lowell, Amelia , McKay, Kelly, Karam, Karam Abi , Pandian, Adithya Shyamala , Pyznar, Gabriel , Xian, Xiaojun, Serhan, Michael

Mayo Clinic

No container title available | February 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-237873/v1 | PMID 33655242 Get It

Abstract Contaminated aerosols and micro droplets are easily generated by infected hosts through sneezing, coughing, speaking and breathing1-3 and harm humans’ health and the global economy. While most of the efforts are usually targeted towards protecting individuals from getting infected,4 eliminating transmissions from infection sources is also important to prevent disease transmission. Supportive therapies for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) pneumonia such as oxygen supplementation, nebulizers and non-invasive mechanical ventilation all carry an increased risk for viral transmission via aerosol to healthcare workers.5-9 In this work, we study the efficacy of five methods for self-containing aerosols emitted from infected subjects undergoing nebulization therapies with a diverse spectrum on oxygen delivery therapies. The work includes five study cases: Case I: Use of a Full-Face Mask with biofilter in bilevel positive airway pressure device (BPAP) therapy, Case II: Use of surgical mask in High Flow Nasal Cannula (HFNC) therapy, Case III: Use of a modified silicone disposable mask in a HFNC therapy, Case IV: Use of a modified silicone disposable mask with a regular nebulizer and normal breathing, Case V: Use of a mitigation box with biofilter in a Non-Invasive Positive Pressure Ventilator (NIPPV). We demonstrate that while cases I, III and IV showed efficacies of 98-100%; cases II and V, which are the most commonly used, resulted with significantly lower efficacies of 10-24% to mitigate the dispersion of nebulization aerosols. Therefore, implementing cases I, III and IV in health care facilities may help battle the contaminations and infections via aerosol transmission during a pandemic.
COVID-19 – Background and Health Sciences Library Response during the First Months of the Pandemic
Clifton, Victoria L. , Flathers, Kristina M. , Brigham, Tara , Brigham, T J

Mayo Clinic

Medical Reference Services Quarterly | February 24, 2021 | Volume: 40 | Issue: 1 | Pages: 1-10

10.1080/02763869.2021.1873611 | PMID 33625334 Get It

Pacific Islanders Searching for Inclusion in Medicine
Taparra, Kekoa

Mayo Clinic

JAMA Health Forum | February 24, 2021 | Volume: 2 | Issue: 2 | Pages: e210153

10.1001/jamahealthforum.2021.0153 | PMID 36218798 Get It

Intensive Care Unit and Hospital Outcomes of Patients Admitted with Blastomycosis: A 14-Year Retrospective Study
Almodallal, Yahya , Alkurashi, Adham K. , Albitar, Hasan Ahmad Hasan , Jenad, Hussam, Prueksaritanond, Suartcha , Tedja, Rudy, Pannu, Bibek , Jagtap, Prashant, Iyer, Vivek , Iyer, Vivek N

Mayo Clinic

No container title available | February 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-220663/v1 Get It

Abstract Introduction: Blastomycosis is an uncommon; potentially life threatening granulomatous fungal infection. The aim of this study is to report hospital and intensive care unit (ICU) outcomes of patients admitted with blastomycosis. Methods: All patients admitted for treatment of blastomycosis at the Mayo Clinic-Rochester, Minnesota between 01/01/2006 and 09/30/2019 were included. Demographics, comorbidities, clinical presentation, ICU admission, and outcomes were reviewed.Results: A total of 84 Patients were identified with 93 unique hospitalizations primarily for blastomycosis. The median age at diagnosis was 49 (IQR 28.1-65, range: 6-85) years and 56 (66.7%) were male. The most frequent comorbidities incl­uded hypertension (n=28, 33.3%); immunosuppressed state (n=25, 29.8%) and diabetes mellitus (n=21, 25%). The lungs were the only organ involved in 56 (66.7%) cases and the infection was disseminated in 19 (22.6%) cases. A total of 29 patients (34.5%) underwent ICU admission due to complications of blastomycosis. ICU related events included mechanical ventilation (n=21, 25%), acute respiratory distress syndrome (ARDS) (n=13, 15.5%), tracheostomy (n=9, 10.7%), renal replacement therapy (n=8, 9.5%), and extracorporeal membrane oxygenation (ECMO) (n=4, 4.8%). A total of 12 patients (14.3%) died in the hospital; all of whom had undergone ICU admission. In-hospital mortality was associated with renal replacement therapy (RRT) (P=0.0255).Conclusions: Blastomycosis is a serious, potentially life-threatening infection that results in significant morbidity and mortality with a 34.5% ICU admission rate. Renal replacement therapy was associated with in-hospital mortality.
Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice
Moaven, Omeed , Mangieri, Christopher W. , Anastasiadis, Panos Z. , Borad, Mitesh J. , W Mangieri, Christopher , A Stauffer, John , Borad, Mitesh J , Moaven, Omeed , Stauffer, John

Mayo Clinic

JCO Precision Oncology | February 24, 2021 | Volume: No volume available | Issue: 5 | Pages: 432-441

10.1200/po.20.00395 | PMID 34250386 Get It

Selective oncotropism and cytolytic activity against tumors have made certain viruses subject to investigation as novel treatment modalities. However, monotherapy with oncolytic viruses (OVs) has shown limited success and modest clinical benefit. The capacity to genetically engineer OVs makes them a desirable platform to design complementary treatment modalities to overcome the existing treatment options' shortcomings. In recent years, our knowledge of interactions of the tumors with the immune system has expanded profoundly. There is a growing body of literature supporting immunomodulatory roles for OVs. The concept of bioengineering these platforms to induce the desired immune response and complement the current immunotherapeutic modalities to make immune-resistant tumors responsive to immunotherapy is under investigation in preclinical and early clinical trials. This review provides an overview of attempts to optimize oncolytic virotherapy as essential components of the multimodality anticancer therapeutic approach and discusses the challenges in translation to clinical practice.
Use of angled hegar dialator for antegrade sizing of the right ventricular outflow tract in tetralogy of Fallot
Krishnan, Prasad

Mayo Clinic

Journal of Cardiac Surgery | February 24, 2021 | Volume: 36 | Issue: 4 | Pages: 1539-1540

10.1111/jocs.15450 | PMID 33625748 Get It

Busulfan-based reduced toxicity conditioning regimen used in hematopoietic stem cell transplantation in HLH patients results in sustained donor chimerism
Goode, Erin , Miller, Holly, Salzberg, Dana, Beebe, Kristen , Schwalbach, Charlotte , Adams, Roberta H. , Ngwube, Alexander , Ngwube, Alexander , Campbell, Courtney

Mayo Clinic

Pediatric Hematology and Oncology | February 24, 2021 | Volume: 38 | Issue: 4 | Pages: 410-416

10.1080/08880018.2020.1868638 | PMID 33625293 Get It